• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed by Alcon Inc.

    5/13/25 4:31:01 PM ET
    $ALC
    Ophthalmic Goods
    Health Care
    Get the next $ALC alert in real time by email
    6-K 1 form6-kxearningsreleaseand.htm 6-K Document

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    _________________
     
    FORM 6-K
    _________________
     
     
    REPORT OF FOREIGN PRIVATE ISSUER
    PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE
    SECURITIES EXCHANGE ACT OF 1934


     
    May 13, 2025
    Commission File Number: 001-31269

    _________________
     

     
    ALCON INC.
    (Registrant Name)



    Rue Louis-d'Affry 6
    1701 Fribourg, Switzerland
    (Address of principal executive office)
    _________________
     



    Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20‑F or Form 40-F: Form 20-F ☒     Form 40-F ☐











    EXHIBIT INDEX
    Exhibit
    Number
    Description
    99.1
    Press release issued by Alcon Inc. dated May 13, 2025
    99.2
    Alcon Inc. Interim Financial Report
    2


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
     
     
     
    ALCON INC.
    Date:May 13, 2025By:/s/ David J. Endicott
    Name: David J. Endicott
    Title: Authorized Representative
    Date:May 13, 2025By:/s/ Timothy C. Stonesifer
    Name: Timothy C. Stonesifer
    Title: Authorized Representative


    3
    Get the next $ALC alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ALC

    DatePrice TargetRatingAnalyst
    5/20/2025Buy → Hold
    Deutsche Bank
    5/14/2025$102.00 → $99.00Buy
    BTIG Research
    3/28/2025$107.00 → $110.00Buy
    Needham
    3/25/2025Neutral → Buy
    BofA Securities
    1/24/2025$108.00 → $106.00Buy
    Needham
    1/10/2025Neutral → Buy
    Redburn Atlantic
    12/17/2024$103.00 → $108.00Buy
    Needham
    11/12/2024Buy
    Needham
    More analyst ratings

    $ALC
    Financials

    Live finance-specific insights

    See more
    • Alcon Reports First-Quarter 2025 Results and Launches Transformational Change in Ophthalmic Surgery with Unity VCS

      First-quarter 2025 sales of $2.5 billion, in line on a reported basis, or up 3% constant currency1 (cc), versus first-quarter 2024 First-quarter 2025 diluted EPS of $0.70; core diluted EPS2 of $0.73 Generated $384 million cash from operations and $278 million free cash flow3 Dividend of CHF 0.28 per share approved by shareholders at the Annual General Meeting on May 6, 2025 Launched rich pipeline of innovative products, including Voyager, Precision7 and Systane Pro PF in Q1 2025; Unity VCS and PanOptix Pro in May 2025 Ad Hoc Announcement Pursuant to Art. 53 LR Alcon (SIX/NYSE:ALC), the global leader in eye care, reported its financial results for the three months ending March 31

      5/13/25 4:30:00 PM ET
      $ALC
      Ophthalmic Goods
      Health Care
    • Alcon Announces Results of 2025 Annual General Meeting

      Shareholders approve all agenda items presented Deborah Di Sanzo elected as new member of the Board 2024 Compensation Report and Report on Non-Financial Matters approved in advisory votes Alcon Inc. (SIX/NYSE:ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced the approval of all proposed resolutions at its 2025 Annual General Meeting ("AGM"). A total of 332,704,408 shares with a nominal value of CHF 0.04 each, representing an aggregate nominal value of CHF 13,308,176.32, were represented at today's AGM. Shareholders re-elected F. Michael Ball as member and Chair of the Board of Directors, and the other members of the Board who stood f

      5/6/25 4:30:00 PM ET
      $ALC
      Ophthalmic Goods
      Health Care
    • Alcon Publishes Agenda for 2025 Annual General Meeting

      Alcon welcomes its shareholders to its third in-person AGM Alcon Board of Directors proposes to elect Deborah Di Sanzo as a new Board member Proposed dividend of CHF 0.28 cash per share Alcon (SIX/NYSE:ALC), the global leader in eye care, will hold its Annual General Meeting (AGM) on May 6, 2025. Alcon is pleased to welcome shareholders to its third in-person AGM since becoming an independent, standalone company. The company looks forward to hearing directly from its shareholders at this open format meeting. Alcon's Board of Directors proposes to the AGM to elect Deborah Di Sanzo as a new Board member. An innovative business leader with more than thirty years of experience in the f

      4/4/25 1:00:00 AM ET
      $ALC
      Ophthalmic Goods
      Health Care

    $ALC
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Alcon Announces FDA Approval of TRYPTYR (acoltremon ophthalmic solution) 0.003% for the Treatment of the Signs and Symptoms of Dry Eye Disease

      In pivotal Phase 3 trials, TRYPTYR demonstrated rapid natural tear production as early as Day 11-2 TRYPTYR is a first-in-class TRPM8 receptor agonist that rapidly stimulates natural tear production in patients with Dry Eye Disease (DED)3 Approximately 38 million individuals in the U.S. are living with DED, yet less than 10% of diagnosed patients are being treated with a prescription product4 Ad hoc announcement pursuant to Art. 53 LR Alcon (SIX/NYSE:ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced the U.S. Food and Drug Administration (FDA) has approved TRYPTYR® (acoltremon ophthalmic solution) 0.003%, formerly known as AR-15512, f

      5/28/25 4:40:00 PM ET
      $ALC
      Ophthalmic Goods
      Health Care
    • Alcon Reports First-Quarter 2025 Results and Launches Transformational Change in Ophthalmic Surgery with Unity VCS

      First-quarter 2025 sales of $2.5 billion, in line on a reported basis, or up 3% constant currency1 (cc), versus first-quarter 2024 First-quarter 2025 diluted EPS of $0.70; core diluted EPS2 of $0.73 Generated $384 million cash from operations and $278 million free cash flow3 Dividend of CHF 0.28 per share approved by shareholders at the Annual General Meeting on May 6, 2025 Launched rich pipeline of innovative products, including Voyager, Precision7 and Systane Pro PF in Q1 2025; Unity VCS and PanOptix Pro in May 2025 Ad Hoc Announcement Pursuant to Art. 53 LR Alcon (SIX/NYSE:ALC), the global leader in eye care, reported its financial results for the three months ending March 31

      5/13/25 4:30:00 PM ET
      $ALC
      Ophthalmic Goods
      Health Care
    • Alcon Announces Results of 2025 Annual General Meeting

      Shareholders approve all agenda items presented Deborah Di Sanzo elected as new member of the Board 2024 Compensation Report and Report on Non-Financial Matters approved in advisory votes Alcon Inc. (SIX/NYSE:ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced the approval of all proposed resolutions at its 2025 Annual General Meeting ("AGM"). A total of 332,704,408 shares with a nominal value of CHF 0.04 each, representing an aggregate nominal value of CHF 13,308,176.32, were represented at today's AGM. Shareholders re-elected F. Michael Ball as member and Chair of the Board of Directors, and the other members of the Board who stood f

      5/6/25 4:30:00 PM ET
      $ALC
      Ophthalmic Goods
      Health Care

    $ALC
    SEC Filings

    See more
    • SEC Form 6-K filed by Alcon Inc.

      6-K - ALCON INC (0001167379) (Filer)

      5/28/25 5:10:23 PM ET
      $ALC
      Ophthalmic Goods
      Health Care
    • SEC Form SD filed by Alcon Inc.

      SD - ALCON INC (0001167379) (Filer)

      5/28/25 11:32:20 AM ET
      $ALC
      Ophthalmic Goods
      Health Care
    • SEC Form 6-K filed by Alcon Inc.

      6-K - ALCON INC (0001167379) (Filer)

      5/13/25 4:31:01 PM ET
      $ALC
      Ophthalmic Goods
      Health Care

    $ALC
    Leadership Updates

    Live Leadership Updates

    See more

    $ALC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Oculis Publishes Results of 2024 Annual General Meeting and Announces Appointments to its Board of Directors and Scientific Advisory Board

      Shareholders approved all agenda items and proposals of the Board of DirectorsRobert K. Warner, M.B.A. and Arshad M. Khanani, M.D., M.A., FASRS elected as members of the Board of DirectorsBaruch D. Kuppermann, M.D., Ph.D. and Frank G. Holz, M.D., Ph.D. appointed as members of the Scientific Advisory BoardOculis established a CHF 50 million flexible loan facility with funds and accounts managed by BlackRock ZUG, Switzerland, May 30, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (NASDAQ:OCS, XICE: OCS))) ("Oculis" or the "Company"), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announced the results from its 2024 Annual General Meeting

      5/30/24 4:00:00 AM ET
      $ALC
      $NARI
      $OCS
      $RXST
      Ophthalmic Goods
      Health Care
      Medical/Dental Instruments
      Biotechnology: Pharmaceutical Preparations
    • SEC Form SC 13G filed by Alcon Inc.

      SC 13G - ALCON INC (0001167379) (Subject)

      2/13/24 3:47:46 PM ET
      $ALC
      Ophthalmic Goods
      Health Care
    • SEC Form SC 13G/A filed by Alcon Inc. (Amendment)

      SC 13G/A - ALCON INC (0001167379) (Subject)

      2/10/23 1:35:38 PM ET
      $ALC
      Ophthalmic Goods
      Health Care
    • SEC Form SC 13G/A filed by Alcon Inc. (Amendment)

      SC 13G/A - ALCON INC (0001167379) (Subject)

      2/10/22 5:01:03 PM ET
      $ALC
      Ophthalmic Goods
      Health Care

    $ALC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Alcon downgraded by Deutsche Bank

      Deutsche Bank downgraded Alcon from Buy to Hold

      5/20/25 8:02:28 AM ET
      $ALC
      Ophthalmic Goods
      Health Care
    • BTIG Research reiterated coverage on Alcon with a new price target

      BTIG Research reiterated coverage of Alcon with a rating of Buy and set a new price target of $99.00 from $102.00 previously

      5/14/25 11:06:26 AM ET
      $ALC
      Ophthalmic Goods
      Health Care
    • Needham reiterated coverage on Alcon with a new price target

      Needham reiterated coverage of Alcon with a rating of Buy and set a new price target of $110.00 from $107.00 previously

      3/28/25 7:39:07 AM ET
      $ALC
      Ophthalmic Goods
      Health Care